References
- Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32(2): 119–35.
- Hays JT, Ebert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359(19): 2018–24.
- Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 64(8): 1269.
- Food and Drug Administration. FDA Med Watch Alert, Varenicline (marketed as Chantix): Information, February 1, 2008, and November 20, 2007. Available at www.fda.gov/cder/drug/infopage/varenicline/default.htm.
- Kuehn BM. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. JAMA 2009; 302(8): 834.
- DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy 2009; 29(7): 852–7.
- Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008; 13(6): 511–4.
- Xi ZX. Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. Drug Health Patient Saf 2010; (2): 39–48.